Place an order request to the broker. The personal manager will contact you to confirm the order.

Order Summary

Asset: Select instrument
Quantity: -
Price per Unit: ? This price is indicative and shown for informational purposes only. The final execution price may change. -
Total Amount: -

Order Expiration

Order remains active until you cancel it or it gets filled

Order expires at the end of the selected day

Order Placed Successfully

Your order has been submitted! Our team will contact you shortly to confirm.

Order Type: -
Asset: -
Quantity: -
Total Amount: -
Manually record a past trade to keep your portfolio up to date. This helps track your P&L accurately.
Total Amount: $0.00

Trade Added Successfully

Trade recorded! Your portfolio data will be recalculated.

Type: -
Asset: -
Quantity: -
Price: -
Total: -

Chat Options

Web Search
Search the internet for recent information
Portfolio Context
Include your portfolio in the conversation
Market Data
Access real-time market information
Watchlist Context
Include your watchlist companies

iShares China Large-Cap ETF (FXI)

2026-05-21T13:34:56.68602+00:00

Key Updates

FXI declined 2.59% to $35.60 since the May 15 report, extending losses to -7.01% YTD as initial diplomatic optimism faded. The ETF has now fallen 4.39% over five days despite constructive developments including improved U.S.-China relations and bullish institutional positioning from UBS and Morgan Stanley. The divergence between positive fundamental catalysts and negative price action suggests profit-taking after the Trump-Xi summit rally, though structural improvements in China's investment case remain intact with valuations at 11x 2027 earnings versus 22x for U.S. equities.

Current Trend

FXI remains in a confirmed downtrend across all timeframes: -1.75% (1-day), -4.39% (5-day), -4.06% (1-month), -8.04% (6-month), and -7.01% YTD. The ETF at $35.60 trades significantly below the $38.08 level reached on May 13 following Trump's Beijing visit, indicating the diplomatic bounce proved temporary. The consistent selling pressure across multiple timeframes reflects sustained risk-off sentiment toward Chinese large-caps despite improving fundamentals. Recent resistance has formed at the $37-38 range, while support appears vulnerable below $35.50.

Investment Thesis

The investment thesis centers on China's re-emergence as an attractive destination driven by economic stabilization, attractive valuations (11x 2027 earnings vs. 22x for U.S. markets), and 15% expected earnings growth matching American levels according to Goldman Sachs data. Key structural supports include resolution of the property crisis, record $1.2 trillion trade surplus in 2025, and improved U.S.-China diplomatic relations following the Trump-Xi summit. The thesis emphasizes China's transition from manufacturing hub to technology innovator, evidenced by major commitments like AstraZeneca's $15 billion investment pledge through 2030. However, foreign direct investment of $80 billion in 2025 remains 77% below the 2021 peak, indicating persistent capital allocation caution among global investors.

Thesis Status

The thesis shows mixed validation. Positive developments include rising global equity fund allocations to Chinese assets from 1.4% in early 2024 to 1.8% by February 2025, $1.22 billion in China ETF inflows post-summit, and Morgan Stanley projecting 8-12% upside through Q2 2027. However, price action contradicts fundamentals, with FXI down 11% from October highs despite improved earnings and diplomatic progress. The gap between institutional bullishness and market performance suggests investors remain cautious, prioritizing liquidity and exit optionality over valuation opportunities. UBS's bullish stance on Chinese tech and reports of potential $30 billion tariff relief framework provide thesis support, but execution risk remains elevated.

Key Drivers

Diplomatic developments dominate near-term catalysts. The Trump-Xi summit produced cautious optimism with discussions on tariff relief covering approximately $30 billion in goods (10% of China's U.S. exports), potentially reducing effective tariff rates by five percentage points. However, Xi's warnings about Taiwan reintroduced geopolitical risk. Technology sector strength provides fundamental support, with Baidu reporting 49% AI revenue growth to 13.6 billion yuan and Zhipu posting 132% revenue growth in 2025. Morgan Stanley's upgraded price targets cite improved earnings, yuan appreciation, and China's strengthening position in global upstream supply chains. The onshore yuan strengthened to 6.784 against the dollar, its strongest level since 2023. Offsetting factors include weak April economic data missing expectations across consumption, industrial output, and investment growth, plus persistent concentration risk in ChiNext with top seven members comprising 60% of index weight.

Technical Analysis

FXI exhibits bearish technical characteristics across all measured timeframes. The ETF broke below the $36 psychological support level, trading at $35.60 with immediate resistance at $36.50-37.00 (5-day moving average region). The May 13 rally to $38.08 established a lower high relative to prior peaks, confirming downtrend structure. Volume patterns suggest distribution, with selling pressure accelerating on the 5-day (-4.39%) and 1-month (-4.06%) timeframes. The 6-month decline of -8.04% indicates sustained institutional repositioning away from Chinese large-caps. Key support lies at $35.00-35.50; a break below would target the $33-34 range. Resistance clusters at $37-38, representing the failed breakout zone from the diplomatic summit. Relative strength versus U.S. indices remains weak, with FXI underperforming despite comparable earnings growth expectations.

Bull Case

  • Valuation discount at historic extremes: Chinese equities trade at 11x 2027 forecast earnings, approximately 50% below U.S. multiples of 22x, while offering comparable 15% earnings growth, creating exceptional risk-reward asymmetry for patient capital. Source: Reuters
  • Institutional capital reallocation accelerating: Global equity fund allocations to Chinese assets increased from 1.4% to 1.8%, with China ETFs receiving $1.22 billion in post-summit inflows, the largest among emerging markets, signaling renewed institutional conviction. Source: Bloomberg
  • Morgan Stanley projects 8-12% upside through Q2 2027: Leading investment bank raised price targets across Chinese indexes citing improved earnings, yuan appreciation, and strengthening position in global upstream supply chains, with specific targets including MSCI China at 91 (12% upside from current levels). Source: CNBC
  • AI ecosystem expansion driving technology sector growth: Baidu reported 49% surge in AI-focused revenue to 13.6 billion yuan, while Zhipu achieved 132% revenue growth in 2025, with UBS identifying Chinese tech as attractive due to strong earnings growth and easing geopolitical tensions. Source: CNBC
  • Potential $30 billion tariff relief framework: U.S. and China are considering tariff reductions on approximately 10% of China's exports to the U.S., potentially lowering effective tariff rates by five percentage points and improving trade dynamics. Source: Bloomberg

Bear Case

  • Foreign direct investment remains 77% below 2021 peak: FDI of $80 billion in 2025 versus $344 billion peak in 2021 demonstrates persistent capital allocation caution, with private equity investors prioritizing liquid, easily-exitable positions over long-term commitments despite improved fundamentals. Source: Reuters
  • Geopolitical risk reintroduced via Taiwan tensions: Xi warned of potential clashes over Taiwan during the Trump summit, reintroducing geopolitical uncertainty that could trigger rapid capital flight and undermine diplomatic progress achieved in recent months. Source: Bloomberg
  • Weak April economic data across all major indicators: Recent data missed expectations across consumption, industrial output, and investment growth, contradicting the stabilization narrative and raising concerns about domestic demand recovery sustainability. Source: CNBC
  • Major China ETFs down 11-33% from October highs: FXI down 11%, MCHI down 13.6%, and KWEB down 33% from October peaks despite positive catalysts, indicating structural selling pressure and lack of conviction among existing holders. Source: CNBC
  • E-commerce margin pressures eroding profitability: Hang Seng Tech stocks including Alibaba and Baidu face margin compression from price wars and advertising competition, with consensus forward earnings estimates falling 26% from July peaks, offsetting hardware sector strength. Source: Bloomberg

CapPilot is AI-powered and can make mistakes. Please double-check responses.

CapPilot leverages generative AI to distill market insights and analysis, as well as answer your questions in chat. While we work hard to ensure accuracy, AI-generated content may occasionally contain inaccuracies or outdated information.

We value your feedback — reporting errors helps us continuously improve.